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Abstract
Background: Symptoms and comorbidities of ankylosing spondylitis (AS) considerably reduce health-related quality
of life (HRQoL) and ability to work. This real-world study assessed rates of tumour necrosis factor inhibitor (TNFi) use
and switching, treatment failure, and associations between failing TNFi and HRQoL, work productivity and activity
impairment (WPAI).
Methods: AS patients and their treating physicians completed questionnaires capturing patient demographics,
clinical status, TNFi treatment history, reasons for switching TNFi, HRQoL and WPAI. Current TNFi was determined
as “failing” if, after ≥3 months, physician-rated disease severity had worsened, remained severe, was “unstable/
deteriorating”, physicians were dissatisfied with disease control and/or did not consider treatment a “success”.
Results: The analysis included 2866 AS patients from 18 countries. Of 2795 patients with complete treatment data,
916 (32.8%) patients had never received TNFi therapy, 1623 (58.1%) patients were receiving their 1st TNFi and 200
(7.2%) patients had ever received ≥2 TNFi (treatment switch). Primary or secondary lack of efficacy were the
commonest reasons for switching, and the mean delay in switching after primary lack of efficacy was 11.1 months.
232 (15.4%) patients on TNFi were currently “failing” who, compared to those with treatment success, reported
poorer HRQoL: 5-dimension EuroQoL (EQ-5D-3 L): 0.63 vs. 0.78; Medical Outcomes Study Short-Form Health Survey
version 2 (SF-36v2) mental component summary (MCS): 41.8 vs. 46.3; physical component summary (PCS): 40.2 vs.
45.1; impaired work productivity: 46.4% vs. 25.0%; and activity: 44.5% vs. 29.6%; all P < 0.001.
Conclusions: Among AS patients, switching TNFi is uncommon and delayed by nearly 1 year despite primary lack
of efficacy. Patients currently failing TNFi experience worse physical function, HRQoL and work productivity.
Keywords: Ankylosing spondylitis, DMARD, Quality of life, Tumour necrosis factor-alpha, Treatment failure
Background
Ankylosing spondylitis (AS) is characterized by inflam-
matory back pain, fatigue and joint swelling from axial
and peripheral articular manifestations as well as comor-
bidities such as uveitis, inflammatory bowel disease,
psoriasis and osteoporotic fractures which pose a signifi-
cant burden to the patient [1, 2]. In addition, spinal
inflammation and structural damage can lead to stiffness
or immobility from vertebral fusions [3]. These painful
and often disabling clinical features have a detrimental
effect on quality of life and mortality as well as burden-
ing the patient and society with impaired ability to work,
substantial healthcare costs and productivity loss [2, 4].
Early diagnosis is important to improve outcomes;
however, diagnosis is often delayed from symptom onset
by as much as 14 years in the USA and 6–8 years in
Europe [5–7]. Diagnosis and treatment delays are corre-
lated with increased radiological severity of AS [5, 8].
Primary pharmacologic treatment of AS are non-
steroidal anti-inflammatory drugs, with biological
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Disease Modifying Anti-Rheumatic Drugs (bDMARDs)
such as tumour necrosis factor inhibitors (TNFi) as a
first-line bDMARD option, and the interleukin (IL)-17A
inhibitors secukinumab and ixekizumab recommended
for patients who have failed TNFi treatment [9]. It is not
uncommon for patients with AS to experience TNFi
therapeutic failure. For example, in a longitudinal, obser-
vational study of 249 cases of AS patients treated with
TNFi, these agents had been discontinued at 1 year in 56
(22.5%) cases. Reasons for TNFi discontinuation in-
cluded lack of efficacy and adverse events in 36.4 and
43.6% of cases, respectively [10]. Interestingly in this
study, patients with RA had lower retention rates than
patients with AS (65.4% vs 77.5%, respectively), which
may reflect fewer options for alternative therapies in AS.
This multinational study was designed to describe use
and switching of TNFi in AS patients; to assess rates of
current TNFi failures and the associations of failing
TNFi treatment with patient-reported health-related
quality of life (HRQoL), work productivity and activity
impairment (WPAI) using real-world data.
Methods
The present study analysed data acquired from the
Adelphi AS Disease Specific Program™ (DSP) from 2015
to 2016 in the following 18 countries: the USA, Canada
(North America), Brazil, Mexico (LatAm), France,
Germany, Italy, Spain, the UK (EU5), Japan, Malaysia,
South Korea, Taiwan, Australia (APAC), Turkey, Egypt,
Saudi Arabia and the United Arab Emirates (T&ME).
DSPs are large multinational point-in-time surveys de-
signed to identify current disease management, and both
patient- and physician-reported disease impact from
real-world clinical practice settings [11]. The DSP was
conducted in line with contemporary legislation, namely
the US Health Insurance Portability and Accountability
Act 1996 [12] and the Health Information Technology
for Economic and Clinical Health Act legislation [13].
DSPs also comply with relevant market research guide-
lines and legal obligations. Data collection was per-
formed in accordance with the European Pharmaceutical
Marketing Research Association guidelines and ethics
committee approval was therefore not required [14]; i.e.
DSPs are non-interventional and no personally identifi-
able protected health information is extracted, though
all patients who participated provided informed consent.
Patients and physicians
Eligible patients were adults over 18 years of age, had a
physician-confirmed diagnosis of AS, were not currently
involved in a clinical trial and visited a participating
physician. Eligible physicians (rheumatologists, and or-
thopedists and internists in Japan) were those who were
treating AS patients and practicing ≥3 years.
Participating physicians completed a questionnaire for
1 to 8 consecutive AS patients. Physicians reported pa-
tient demographics, clinical assessments, medication use
and treatment history; responses were based on data
available from treatment records. Patients were then
invited to complete a voluntary patient-reported ques-
tionnaire. The questionnaires included the 5-dimension
EuroQoL (EQ-5D-3 L) [15, 16], Medical Outcomes
Study Short-Form Health Survey version 2 (SF-36v2)
[17, 18] and WPAI General Health [19]. Questionnaires
were completed independently from physicians and
returned in sealed envelopes to ensure confidentiality.
Definitions
To be eligible for assessment of treatment response pa-
tients had to be exposed to a TNFi ≥3 months. “TNFi
switching” was defined as a change from one TNFi to
another. The reasons for switching from 1st to 2nd TNFi
were selected by physicians from a list of choices includ-
ing primary lack of efficacy (initial non-response) or
secondary lack of efficacy (loss of response over time),
patient change (improvement, worsening of condition),
lack of tolerability, patient preference, administrative
reasons (i.e. formulary requirements) and physician pref-
erence for an alternative therapy; Fig. 1 provides the full
list of options; no additional explanation of the options
were provided so results represent physicians’ real-world
interpretation of reasons.
Patients were defined as “failing TNFi” if, after ≥3
months of treatment with their current TNFi therapy, at
least one of the following criteria (assessed by the treat-
ing physician) was met: disease severity (mild, moderate
or severe) had worsened or remained severe; disease
activity (improving, stable, unstable or deteriorating) was
unstable or deteriorating; or physician reported dissatis-
faction with current control of AS. Any patient not
defined as “failing TNFi” was defined as “TNFi success”.
Statistical analyses
Analyses were performed at both global and regional
levels. Categorical variables are presented as counts and
proportion of respondents. Continuous numerical vari-
ables are presented as means and standard deviations
(SD). Pearson’s χ2 test was used to evaluate differences
in failure rates by lines of TNFi.
Patient characteristics were analyzed descriptively and
included demographics (age, gender and Body Mass
Index [BMI]), human leukocyte antigen B27 (HLA-B27)
status, number of TNFi therapies ever received, duration
patients remained on 1st TNFi before switching, reasons
for switching from 1st to 2nd TNFi, and proportions of
patients currently failing TNFi overall and at each line of
therapy.
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Linear regression analyses were used for EQ-5D-3 L,
SF-36v2 (physical component summary [PCS] and men-
tal component summary [MCS]) scores and WPAI.
Treatment response (failing TNFi or TNFi success) was
the independent variable; differences in age, gender,
BMI, smoking status, time since symptom onset and
region were controlled for. Predicted values for all
outcomes were subsequently stratified by TNFi failure or
success. All other variables were fixed at their means.
Stata Statistical Software: Release 15 (StataCorp LP,
College Station, TX) was used for all analyses.
Results
Patients characteristics
Six-hundred and forty physicians (North America, n =
97; LatAm, n = 31; EU5, n = 299; APAC, n = 115; T&ME,
n = 98) and 2866 AS patients (North America, n = 538;
LatAm, n = 139; EU5, n = 1512; APAC, n = 353; T&ME,
n = 324) from 18 countries participated in the study;
1406 patients (49%) completed the voluntary patient
questionnaires including EQ-5D-3 L (n = 1382), SF-36v2
(n = 1402) and WPAI (n = 1352).
Patient characteristics such as mean age, BMI, time
since diagnosis, Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) and Bath Ankylosing
Spondylitis Functional Index were similar across most
regions, although differences were noted mostly in
T&ME patients (see Additional file 1: Table S1). In
T&ME patients, mean age was < 40 years (37.5 years),
whereas in all other regions the mean age was > 40 years.
Mean time since symptom onset ranged from 2.8 years
in T&ME to 10.8 years in North America, and mean
time since diagnosis ranged from 1.5 years in T&ME to
7.3 years in North America. The proportion of patients
classified as “severe” by their treating physician ranged
from 3.6% in Latin America to 7.7% in T&ME. Median
BASDAI scores ranged from 2.5 in T&ME to 4.0 in
North America for the subset of patients in whom data
was available.
TNFi use and switching
Of the 2795 (of 2866) patients with complete treatment
data, 916 (32.8%) had never received a TNFi, 1623
(58.1%) had received one, 200 (7.2%) two, and 56 (2.0%)
three or more TNFi (Table 1). The mean (SD) disease
durations for these groups of patients were 4.4 (7.2), 6.3
(7.3), 9.5 (7.7) and 13.0 (8.0) years, respectively.
In 242 patients where information for switching from
1st to 2nd TNFi therapy was available, the commonest
reason was lack of efficacy in over half of patients.
Secondary lack of efficacy (loss of response over time)
was reported in 106 (43.8%) patients, and primary lack
of efficacy (initial non-response) in 39 patients (16.1%)
(Fig. 1). Other reasons for switching from 1st TNFi
therapy were “condition worsened” (n = 85; 35.1%),
“remission not induced” (n = 50; 20.7%), “lack of
alleviation of pain” (n = 47; 19.4%) and “remission not
maintained” (n = 38; 15.7%).
Fig. 1 Physician-reported reasons given for patient switching from 1st to 2nd line TNFi. * Secondary lack of efficacy: loss of response over time; †
I wanted to use bDMARD that can be used as a monotherapy; ‡ I wanted to use a bDMARD that can be used in combination. MOA: Mode of
action; bDMARD: biologic Disease Modifying Anti Rheumatic Drug
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Information on treatment duration was available for
34 of the 39 patients who switched therapy due to pri-
mary lack of efficacy. These patients remained on the
failed therapy for a mean (SD) of 11.1 months (10.2) be-
fore treatment was switched. The longest reported time
to switch was 36months (Table 1).
Patients currently “failing TNFi”
Treatment success or failure was evaluated in 1507/2866
patients. A total of 916 patients were excluded as they
had never received TNFi, 90 were not currently receiv-
ing TNFi, 182 were exposed to TNFi < 3 months, 100
had missing duration of TNFi treatment data and 71 had
other missing treatment data. Globally, 232 (15.4%)
patients were failing current TNFi according to the
definitions provided and failure rates were higher with
each successive TNFi. Among patients with data avail-
able on the number of TNFi ever received, 13.9% were
failing their 1st TNFi. Globally, failure rates increased to
28.6% in patients receiving their 3rd (or later) TNFi (P =
0.0089). In North America and EU5, 16.2% (North
America) and 10.3% (EU5) of patients were failing 1st
TNFi, and 36.4% (North America; P = 0.2062) and 26.9%
(EU5; P = 0.0111) were failing their 3rd (or later) TNFi.
For regions with lower patient numbers, the trend again
increased with subsequent TNFi (either 2nd or 3rd, if
available) (Fig. 2).
Patient characteristics by failing TNFi and TNFi success
groups
With some exceptions, patient characteristics between
failing and successful TNFi groups were similar in most
regions (Table 2). Patients with treatment success were
more likely male in EU5 but no other regions (Table 2).
Globally, patients who were failing TNFi had more AS
symptoms compared with TNFi successes (2.5 vs. 1.8,
P < 0.0001), as observed in North America (3.1 vs. 2.1;
P = 0.0003), EU5 (2.4 vs. 1.6; P < 0.0001) and APAC (2.3
vs. 1.8, P = 0.0203) but not in LatAm or T&ME (Table
2). Globally, both erythrocyte sedimentation rate (ESR)
(24.9 vs. 15.1; P < 0.0001) and C-reactive protein (CRP)
(7.2 vs. 4.5; P < 0.0001) levels were higher in patients
failing compared with TNFi treatment success groups
(Table 2).
Association between failing current TNFi and HRQoL and
WPAI
Linear regression analysis exposed that failing treatment
compared with treatment success was associated with a
lower HRQoL, shown by the impact on the adjusted
EQ-5D-3 L (0.63 vs. 0.78, coef. -0.149, P < 0.0001), and
SF-36v2 PCS (40.2 vs. 45.1, coef. -4.917, P < 0.0001) and
MCS scores (41.8 vs. 46.3, coef. -4.511, P < 0.0001)
(Fig. 3a and b). All SF-36 domain scores were lower
among patients failing TNFi treatment compared with
those with treatment success (Fig. 4). Among those
working, WPAI overall work productivity was confirmed
as worse in patients failing vs. not failing (46.4% vs.
25.0%, coef. 21.397, P < 0.0001), as was absenteeism
(11.2% vs. 5.1%, coef. 6.035, P = 0.007) and presenteeism
(43.1% vs. 22.4%, coef. 20.758, P < 0.0001), and impair-
ment in daily activities in the entire population (44.5%
vs. 29.6%, coef. 14.961, P < 0.0001) (Fig. 3c).
Discussion
This real-world, large multinational study of TNFi use in
patients with AS demonstrates that TNFi do not consist-
ently deliver sustained efficacy; switching was mainly
associated with primary and secondary treatment
failures, i.e. primary and secondary lack of efficacy, and
Table 1 Patient TNFi therapy exposure and bDMARD switching
All
(n = 2795)
North America
(n = 530)
LatAm
(n = 137)
EU5
(n = 1478)
APAC
(n = 335)
T&ME
(n = 315)
Number of previous TNFi therapies ever
received, n (%)
0 916 (32.8) 108 (20.4) 15 (10.9) 535 (36.2) 103 (30.7) 155 (49.2)
1 1623 (58.1) 347 (65.5) 113 (82.5) 821 (55.5) 194 (57.9) 148 (47.0)
2 200 (7.2) 60 (11.3) 9 (6.6) 89 (6.0) 31 (9.3) 11 (3.5)
3+ 56 (2.0) 15 (2.8) 0 (0.0) 33 (2.2) 7 (2.1) 1 (0.3)
Time on 1st bDMARD despite primary lack of
efficacy, months
(n = 34) (n = 16) (n = 13) (n = 2) (n = 3)
Mean (SD) 11.1 (10.2) 12.6 (11.6) – 10.7 (9.7) 1 (0.0) 11.3 (5.0)
Median 9.5 11.0 – 9.0 1.0 12.0
Min, Max 0.0–36.0 2.0–36.0 – 0.0–36.0 1.0–1.0 6.0–16.0
IQR 0.0, 1.0 0.0, 1.5 0.0, 0.0 0.0, 1.0 0.0, 0.5 0.0, 0.0
Abbreviations: APAC Asia Pacific region, bDMARD biological disease modifying anti-rheumatic drug; BMI body mass index, EU5 European Union 5, IQR interquartile
range, LatAm Latin America, T&ME Turkey and Middle East, SD standard deviation, TNFi tumour necrosis factor inhibitor
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many patients were failing their current TNFi. Clinical
responses to TNFi declined with each subsequent treat-
ment, evidenced by a higher incidence currently failing
their 2nd or 3rd TNFi. Our cross-sectional data analysis
allows us to report the rates of patients currently failing
therapy they are still taking, based on their clinical pro-
file. This differs from previous studies [20–22], where
failure rates were calculated based on the proportion of
patients who switched therapy as an indicator of failure.
The most common reasons for switching in our study
were secondary and primary lack of efficacy (43.8 and
16.1%, respectively), worsening of condition (35.1%),
remission not induced or maintained (20.7 and 15.7%,
respectively), and lack of alleviation of pain (19.4%) and
lack of tolerability (12.0%), consistent with previous
reports [23, 24]. Data reported in our study reflect physi-
cians’ responses, and thus their real-world reasoning for
switching therapy, even though there may be potential
overlaps in the responses. A recent review from 21
studies reported the most common reasons for switching
to a 2nd TNFi were lack of efficacy (14–68%), loss of ef-
ficacy (13–61%) and adverse events/poor tolerability
(13–57%) [25]. Lack of efficacy or adverse events (AE)
after the 1st TNFi may justify switching to another TNFi
on the basis that they differ in structure, immunogen-
icity, half-life and administration schedules [23, 24]. This
is supported by the common observation that patients
who switched because of loss of response over time, due
to adverse events or other reasons, were more likely to
respond to a 2nd TNFi than patients with a primary (ini-
tial) lack of response [25].
In cases where physicians reported switching from 1st
to 2nd TNFi therapy was due to primary lack of efficacy,
time to switch to the 2nd TNFi occurred at 11.1 months
on average. Our global findings are consistent with data
from a retrospective analysis of patients treated with
TNFi at two British hospitals where the mean duration
of treatment prior to switching in patients with
Fig. 2 Rates of TNFi failure on successive lines of TNFi therapy. APAC, Asia Pacific region; EU5, European Union 5; T&ME, Turkey and Middle East
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Fig. 4 Results are adjusted for age, gender, BMI, smoking status, time since symptom onset and region
Fig. 3 Results are adjusted for age, gender, smoking status, BMI, time since onset of symptoms and region. ABS, absenteeism; ACT, activity
impairment; APAC, Asia Pacific region; EU5, European Union 5; LatAm, Latin America; O, overall work impairment; PRES, presenteeism; SD,
standard deviation; T&ME, Turkey and Middle East. SF-PCS, P < 0.0001; SF-MCS, P = 0.0004; overall work impairment, P < 0.0001; presenteeism, P <
0.0001; absenteeism, P = 0.0073; activity impairment, P < 0.0001
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inadequate efficacy was 11 months [26]. These find-
ings indicate that patients may be maintained on fail-
ing therapy for significantly longer than the 12 weeks
recommended by ACR/SAA/SPARTAN treatment
guidelines [9].
Our analyses also demonstrate that failing TNFi ther-
apy is associated with poorer patient-reported HRQoL,
as measured by EQ-5D-3 L and SF-36, as well as nega-
tive impact on daily activities measured by WPAI.
Analysis of SF-36 highlighted that failing TNFi treatment
is associated with poorer outcomes across all domains
associated with HRQoL, despite the fact that differences
between patient groups in MCS and PCS scores were
not large. Future studies are needed to confirm our
results and examine the clinical relevance of these find-
ings. Although absenteeism and presenteeism are com-
mon in patients with AS, which has been shown to
negatively impact HRQoL [4, 27], to the best of our
knowledge, this is the first real-world study to compare
HRQoL and WPAI in patients with successful vs. failing
TNFi treatment. The impact of time to switch to an-
other TNFi on HRQoL, and economic and social burden
of AS, was not explored in this study but it is an area of
interest for future research.
TNFi treatment failure is an important consideration
in the management of AS patients, since until recently
TNFi were the only approved biologic treatment for AS.
Following the recent approvals of the IL-17A antagonists
secukinumab and ixekizumab, the ACR/SAA/SPARTAN
recommendations include switching to either [9] as they
are demonstrated effective in patients with inadequate
response to TNFi, providing an option for those whose
disease is not controlled by TNFi therapy [28, 29]. At
the time of this study, TNFi were the only biologic ther-
apy available, therefore the real-world clinical impact of
switching to a new class of biologics such as secukinu-
mab or ixekizumab could not be assessed and represents
an important area of future research.
A major strength of this study is that it presents real-
world data in patients with a clinically confirmed diag-
nosis of AS around the world, providing insight into
rates of TNFi use and switching, as well as the negative
impact on patients’ HRQoL and work productivity asso-
ciated with failing TNFi therapy.
Several potential limitations associated with data
derived from this cross-sectional, real-world study
should be considered. A primary limitation of the ana-
lysis is that the source data is a point-in time survey and
does not capture the exact timepoint at which patients
fail to respond to therapy, therefore it was necessary to
rely on physician-reported reasons for switching therapy
to identify the subset who failed to respond. Cross-
sectional studies are limited in their selection of patients,
sample size and data collection. The high rate of patients
receiving TNFi in countries where access to biologics is
limited (LatAm) may be impacted by small physician
and patient sample size and reflect a selection bias. In
contrast to a clinical trial where disease severity and
activity are assessed by validated measures, physician
ratings of disease severity/activity may be considered
subjective, and hence a limitation. However, our study
reflects how physicians’ practice in a real-world clinical
setting where assessments may be more holistic rather
than focusing solely on disease activity. Finally, although
recall bias is a common limitation of surveys, as data
were collected at the time of patients’ appointments, the
likelihood of recall bias is reduced.
Conclusions
In conclusion, this large multinational real-world study
of AS patients demonstrated that lack or loss of efficacy
of TNFi is common, yet it appears that patients failing
the 1st TNFi (primary lack of efficacy/failure) are not
switched to another TNFi for nearly 1 year. A significant
proportion of patients who failed their 1st TNFi did not
respond to subsequent TNFi. Failing TNFi therapy is
associated with poorer HRQoL, physical activity and
work productivity. Whether regular monitoring and earl-
ier use of appropriate therapies upon identification of
lack of efficacy leads to improvements in symptom con-
trol and HRQoL remains to be seen.
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